Today: 13 March 2026
Subscribe

Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

Microsoft stock slips early as big tech softens; Wedbush flags FY26 as AI “inflection year”

Microsoft stock slips early as big tech softens; Wedbush flags FY26 as AI “inflection year”

Microsoft shares fell 0.8% to $483.62 in early Friday trading as U.S. markets opened for 2026. Analyst Dan Ives of Wedbush maintained a $625 price target, calling fiscal 2026 an AI “inflection” year for Microsoft. The broader Nasdaq 100 also slipped 0.8%. Investors awaited U.S. economic data for signals on interest rates.
2 January 2026
···
Tesla stock today: TSLA slips after Q4 deliveries drop, earnings date set

Tesla stock today: TSLA slips after Q4 deliveries drop, earnings date set

Tesla shares fell about 1% in early New York trading after fourth-quarter vehicle deliveries missed Wall Street estimates, with 418,227 vehicles delivered versus 434,487 expected. The company scheduled Q4 earnings for Jan. 28 and reported record energy storage deployments. BYD outsold Tesla in 2025, delivering 2.26 million battery-electric vehicles. U.S. and European markets showed mixed demand signals.
2 January 2026
··
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

Axsome Therapeutics shares surged 22.9% to $182.64 on Dec. 31 after the FDA accepted its AXS-05 filing for Alzheimer’s disease agitation and set an April 30, 2026 target action date. The company also said it plans to submit an NDA for AXS-12 in narcolepsy in January, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
2 January 2026
·
UiPath stock set for Jan. 2 open after CEO share sale, S&P MidCap 400 entry looms (PATH)

UiPath stock set for Jan. 2 open after CEO share sale, S&P MidCap 400 entry looms (PATH)

UiPath shares closed at $16.39, down 1.7% on Dec. 31, after CEO Daniel Dines sold 90,000 shares for about $1.5 million under a pre-set plan, a filing showed. The company is set to join the S&P MidCap 400 before Friday’s open, replacing Synovus Financial. Shares last traded at $16.34 after hours. U.S. markets were closed Thursday for New Year’s Day.
2 January 2026
····
Super Micro Computer (SMCI) stock ends 2025 lower after SuperBlade liquid-cooling push — what investors watch next

Super Micro Computer (SMCI) stock ends 2025 lower after SuperBlade liquid-cooling push — what investors watch next

Super Micro Computer shares closed down 1.28% at $29.27 on Wednesday, the last trading day of 2025. The company introduced a new 6U SuperBlade system using Intel Xeon 6900-series chips and liquid cooling. Supermicro projected fiscal Q2 net sales of $10–11 billion and fiscal 2026 sales of at least $36 billion. Its last quarterly report missed estimates after a major customer delayed deliveries.
2 January 2026
··
Ford stock closes 2025 at $13.12 as Wall Street slips; what investors watch next for NYSE:F

Ford stock closes 2025 at $13.12 as Wall Street slips; what investors watch next for NYSE:F

Ford shares closed down 0.83% at $13.12 in the final U.S. trading session of 2025, mirroring declines in GM and Tesla as the S&P 500 fell 0.74%. Ford enters 2026 after a $19.5 billion EV writedown and will report Q4 and full-year results on Feb. 10. U.S. markets are closed Jan. 1 for New Year’s Day, reopening Jan. 2. Investors await the next Federal Reserve policy meeting on Jan. 27–28.
2 January 2026
·
DJT stock rises as Trump Media pitches shareholder crypto token, expands Truth Social ETF push

DJT stock rises as Trump Media pitches shareholder crypto token, expands Truth Social ETF push

Trump Media & Technology Group shares closed up 5.4% at $13.25 on Dec. 31 after announcing a plan to distribute a new digital token to shareholders via Crypto.com’s Cronos blockchain. The company also launched five Truth Social-branded ETFs on the NYSE under its Truth.Fi brand. U.S. markets were closed Jan. 1 for the holiday. More details on the token plan are expected in the new year.
2 January 2026
··
SoFi stock price today: SOFI closes lower ahead of 2026 as traders brace for rates and January data

SoFi stock price today: SOFI closes lower ahead of 2026 as traders brace for rates and January data

SoFi Technologies shares closed down 1.4% at $26.18 on Wednesday, trading between $26.08 and $26.90 as about 34 million shares changed hands. The S&P 500 slipped 0.74% and the Nasdaq lost 0.76% in light holiday-week volume. The 10-year Treasury yield rose to 4.163% after a drop in weekly jobless claims. U.S. markets were closed Thursday for New Year’s Day.
2 January 2026
··
1 … 416 417 418 419 420 … 703

Stock Market Today

  • Mullen Group (TSX:MTL) Sees Analyst Target Updates and Buyback Moves
    March 13, 2026, 5:05 PM EDT. Mullen Group's fair value estimate marginally rose to CA$18.83, reflecting evolving analyst perspectives. CIBC increased its price target to CA$17, keeping a Neutral rating, signaling a balance between growth potential and execution risks. Scotiabank raised its target by CA$2.50, highlighting confidence in company strategy. Analysts show mixed views, with targets mostly between CA$17 and CA$18.75, suggesting the current price largely factors expected performance. Revenue growth and profit margins remain steady, with minor adjustments to valuation multiples. Key developments include acquisitions like Cole Group and the shift towards asset-light logistics, impacting future revenue and margins. Investors watch supply chain reshoring and e-commerce growth as influence factors. These updates offer a nuanced view of Mullen Group's financial outlook and strategic evolution.
Go toTop